166 related articles for article (PubMed ID: 32321399)
1. An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL).
Mansuri R; Singh J; Diwan A
Curr Drug Targets; 2020; 21(11):1105-1129. PubMed ID: 32321399
[TBL] [Abstract][Full Text] [Related]
2. Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis.
Singh K; Garg G; Ali V
Curr Drug Metab; 2016; 17(9):897-919. PubMed ID: 27549807
[TBL] [Abstract][Full Text] [Related]
3. Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
Datta AK; Datta R; Sen B
Adv Exp Med Biol; 2008; 625():116-32. PubMed ID: 18365663
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets and pathways for the treatment of visceral leishmaniasis.
Jain V; Jain K
Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
[TBL] [Abstract][Full Text] [Related]
5. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
[TBL] [Abstract][Full Text] [Related]
6. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
7. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão JQ; Pita Pedro DP; Coelho AC
Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
9. Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings.
Santana W; de Oliveira SSC; Ramos MH; Santos ALS; Dolabella SS; Souto EB; Severino P; Jain S
Chem Biodivers; 2021 Sep; 18(9):e2100336. PubMed ID: 34369662
[TBL] [Abstract][Full Text] [Related]
10. Developments in the treatment of visceral leishmaniasis.
den Boer ML; Alvar J; Davidson RN; Ritmeijer K; Balasegaram M
Expert Opin Emerg Drugs; 2009 Sep; 14(3):395-410. PubMed ID: 19708817
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.
Chattopadhyay A; Jafurulla M
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):7-12. PubMed ID: 22100811
[TBL] [Abstract][Full Text] [Related]
12. Leishmania spp.: proficiency of drug-resistant parasites.
Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
[TBL] [Abstract][Full Text] [Related]
13. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.
Singh OP; Singh B; Chakravarty J; Sundar S
Infect Dis Poverty; 2016 Mar; 5():19. PubMed ID: 26951132
[TBL] [Abstract][Full Text] [Related]
14. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
15. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
[TBL] [Abstract][Full Text] [Related]
16. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
17. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
[TBL] [Abstract][Full Text] [Related]
18. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
Croft SL; Coombs GH
Trends Parasitol; 2003 Nov; 19(11):502-8. PubMed ID: 14580961
[No Abstract] [Full Text] [Related]
19. Unique thiol metabolism in trypanosomatids: Redox homeostasis and drug resistance.
Ali V; Behera S; Nawaz A; Equbal A; Pandey K
Adv Parasitol; 2022; 117():75-155. PubMed ID: 35878950
[TBL] [Abstract][Full Text] [Related]
20. Recent understanding in the treatment of visceral leishmaniasis.
Rosenthal E; Marty P
J Postgrad Med; 2003; 49(1):61-8. PubMed ID: 12865573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
